Yüksek doz kemoterapi, otolog kemik iliği veya periferik stem cell transplantasyonu yapılacak non-Hodgkin lenfomalı hastalarda fitohemaglutinin'e cevabın araştırılması

The investigation of the responses to phytohemagglutinin in the patients of non-Hodgkin's lymphoma who were candidates for high dose chemotherapy, autologous bone marrow or peripheral stem cell transplantation

Abstract

Phytohemagglutinin (PHA) is principally a T lymphocyte mitogen, producing a greater stimulatory effect* on CD4+ helper/inducer T lymphocytes than on CD8+ suppressor/cytotoxic T cells. In this study, investigated if there are differences in the mitogenic response to PHA between autologous bone marrow " (BM) and granulocyte-monocyte colony stimulating factor (GM-CSF)-mobilized peripheral stem cell (PSC) products as well as to normal peripheral blood leukocytes (PBL). BM and PSC products from 24 patients with non-Hodgkin's lymphoma (NHL) were collected and assays of cell proliferation in response to PHA were performed both before and following 5 days co-incubation with IL^2. The proliferative response to PHA by cells from both PSC and BM products were significantly lower than normal PBL (p

Özet

Fitohemaglutinin (PHA), genellikle bir T lenfosit mitojenidir. CD4+ helper/inducer T lenfositlerine, CD8' suppressor/cytotoxic T lenfositlerine göre daha fazla stimulator etki yapar. Bu çalışmada, biz normal periferik kan lökositleri (PBL) ile otolog kemik iliği (BM) ve granulosit-monosit koloni stîmulan faktör (GM-CSF) ile mobilize edilmiş periferik stem cell (PSC) ürünlerinin PHA 'e verdikleri mitojenik cevapların farklı olup olmadığını araştırdık. Non-Hodgkin lenfomalı 24 hastadan kemik iliği ve periferik stem cell ürünleri toplandı ve IL-2 ile 5 gün kültür yapılmadan önce ve yapıldıktan sonra PHA hücre proliferasyon cevabı incelendi. Hem PSC hem de BM hücrelerinin PHA proliferatif cevapları anlamlı şekilde normal PBL 'den düşüktü (p